HDAC2-dependent Antipsychotic-like Effects of Chronic Treatment with the HDAC Inhibitor SAHA in Mice
- 1 September 2018
- journal article
- research article
- Published by Elsevier in Neuroscience
- Vol. 388, 102-117
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (MH111940, R01 MH084894, 16K19786, 15H06719, JSPS 23-3454)
- Japan Society for the Promotion of Science (MH111940, R01 MH084894, 16K19786, 15H06719, JSPS 23-3454)
- Marie Curie (MH111940, R01 MH084894, 16K19786, 15H06719, JSPS 23-3454)
- Uehara Memorial Foundation (MH111940, R01 MH084894, 16K19786, 15H06719, JSPS 23-3454)
This publication has 71 references indexed in Scilit:
- Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout MiceMolecular Pharmacology, 2013
- Update on Typical and Atypical Antipsychotic DrugsAnnual Review of Medicine, 2013
- The Potential of HDAC Inhibitors as Cognitive EnhancersAnnual Review of Pharmacology and Toxicology, 2013
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agentsMolecular Psychiatry, 2012
- Treating Impaired Cognition in SchizophreniaCurrent Pharmaceutical Biotechnology, 2012
- Sodium valproate: an old drug with new rolesTrends in Pharmacological Sciences, 2009
- HDAC2 negatively regulates memory formation and synaptic plasticityNature, 2009
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disordersCurrent Opinion in Pharmacology, 2008
- Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Medicine, 2005
- The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with SchizophreniaThe British Journal of Psychiatry, 1993